151619-12-4

Basic information

• Product Name: Benzofuran, 6-chloro-
• Synonyms: Benzofuran, 6-chloro-;6-Chloro-1-benzofuran;6-chlorobenzofuran
• CAS NO: 151619-12-4
• Molecular Formula: C₈H₅ClO
• Molecular Weight: 152.58
• Mol File: 151619-12-4.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 202-203 °C
• Appearance: /
• Density: 1.289±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: Benzofuran, 6-chloro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzofuran, 6-chloro-(151619-12-4)
• EPA Substance Registry System: Benzofuran, 6-chloro-(151619-12-4)

Safety Data

• Hazardous Substances Data: 151619-12-4(Hazardous Substances Data)

Upstream product

• 86912-81-4 (3-chlorophenoxy)acetaldehyde diethyl acetal 
• 108-43-0 3-monochlorophenol 
• 3260-78-4 6-chlorobenzofuran-3(2H)-one 
• 2420-26-0 4-chlorosalicylaldehyde 

Relevant articles and documents

TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE

The invention provides a variety of compounds having the structure of Formula I and uses of such compounds for treatment of various indications, including cancer as well as methods of treatment involving such compounds are also provided. The uses of the compounds may specifically include: bladder cancer, cholangiocarcinoma; colorectal cancer; diffuse large B-cell lymphoma (DLBC); liver cancer; ovarian cancer; thymoma; thyroid cancer; clear cell renal cell carcinoma (CCRCC); chromophobe renal cell carcinoma (ChRCC); prostate cancer; breast cancer; uterine cancer; pancreatic cancer; cervical cancer; uveal melanoma; acute myeloid leukemia (AML); head and neck cancer; small cell lung cancer (SCLC); lung adenocarcinoma sarcoma; mesothelioma; adenoid cystic carcinoma (ACC), sarcoma; testicular germ cell cancer; uterine cancer; pheochromocytoma and paraganglioma (PCPG); melanoma; glioma; glioblastoma multiforme; T-cell Acute Lymphoblastic Leukemia; T-cell Lympohoma, medulloblastoma; and neuroblastoma.

OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF

The present disclosure relates to oxadiazine compounds, pharmaceutical compositions comprising an effective amount of an oxadiazine compound and methods for using an oxadiazine compound in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of an oxadiazine compound.

GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES

Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).